WO2005089742A1 - 頻尿または尿失禁の予防または治療用医薬 - Google Patents
頻尿または尿失禁の予防または治療用医薬 Download PDFInfo
- Publication number
- WO2005089742A1 WO2005089742A1 PCT/JP2005/004825 JP2005004825W WO2005089742A1 WO 2005089742 A1 WO2005089742 A1 WO 2005089742A1 JP 2005004825 W JP2005004825 W JP 2005004825W WO 2005089742 A1 WO2005089742 A1 WO 2005089742A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acceptable salt
- pharmacologically acceptable
- acid derivative
- urinary incontinence
- general formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
Definitions
- the present invention relates to a medicament useful for the prevention or treatment of frequent urination or urinary incontinence.
- the present invention provides a general formula
- the present invention relates to a medicament for the prevention or treatment of frequent urination or urinary incontinence characterized by combining with a 1-adrenergic receptor (hereinafter referred to as “a 1-ARj t”).
- a 1-ARj t 1-adrenergic receptor
- Non-Patent Document 1 discloses a method for treating neurological disorders.
- drugs which are the center of pharmacotherapy, are concerned about side effects such as rheumatoid arthritis, constipation, drainage disorders, and central nervous system symptoms.
- a 1-AR blockers such as silodosin, tamsulosin, and urapidil are known to improve urethral resistance by relaxing the urethral smooth muscle by (X 1-AR blocking action.
- Patent Document 1 International Publication No. 00/02846 Pamphlet
- Patent Document 2 International Publication No. 99/15202 Pamphlet
- Patent Document 3 Japanese Patent Publication No. 62-52742
- Patent Document 4 Japanese Patent Laid-Open No. 2001-288115
- Patent Document 5 International Publication 00/00187 Pamphlet
- Patent Document 6 International Publication No. 02/069906 Pamphlet
- Non-patent literature l Scope, Falumasia Co., Ltd., 2003, No. 42, No. 1, p. 14-15
- Non-patent literature 2 Medicinal Journal, Medicinal Journal, 1997, No. 33, No. S-1 , P.193-197 Disclosure of the invention
- An object of the present invention is to provide a medicament useful as a preventive or therapeutic agent for frequent urination or urinary incontinence.
- the present invention exhibits the following excellent urinary bladder pressure-reducing action and urination interval extending effect, and is useful as a preventive or therapeutic drug for frequent urination or urinary incontinence, or the following pharmacologically acceptable Or a hydrate or solvate thereof, and an a 1-AR blocker in combination.
- the present invention provides:
- Dose power of tamsulosin or a pharmacologically acceptable salt thereof The medicament according to (4), wherein the oral dose of tamsulosin hydrochloride to an adult is 0.1 to 0.8 mg / day;
- the present invention relates to a method for preventing or treating frequent urination or incontinence;
- the present invention will be described in detail.
- a phenoxyacetic acid derivative represented by the general formula (I) is used in combination with an oc 1-AR blocker, an anesthetized rat intravesical pressure test is performed.
- the phenoxy represented by the general formula (I) is used for the prevention or treatment of frequent urination or urinary incontinence. It is extremely effective to use a combination of an acetic acid derivative and an a 1-AR blocker.
- examples of the lower alkoxy group for R 1 include a methoxy group, an ethoxy group, a propoxy group, a butoxy group, an isobutyloxy group, a sec-butyloxy group, a tert-butyloxy group, and a pentyloxy group. , Isopentyloxy group, hexyloxy group and the like, and straight-chain and branched alkoxy groups having 11 to 6 carbon atoms.
- the phenoxyacetic acid derivatives represented by the general formula (I) include (1) 2- [4 [2— [[(IS, 2R) — 2-hydroxy-2- (4-hydroxyphenol)] —1-Methylethyl] amino] ethyl] -2,5-dimethylphenoxy] ethyl acetate (hereinafter “compound 1” t) is preferred!
- the phenoxyacetic acid derivative represented by the general formula (I) can be produced by a method described in the literature (for example, see Patent Document 1).
- the phenoxyacetic acid derivative represented by the general formula (I) can be converted into a pharmacologically acceptable salt thereof by a conventional method.
- salts include salts with inorganic acids such as hydrochloric acid, hydrobromic acid, yowi hydroacid, sulfuric acid, nitric acid, phosphoric acid, carbonic acid; formic acid, acetic acid, propionic acid, citrate, succinate.
- Acid tartaric acid, fumaric acid, butyric acid, oxalic acid, malonic acid, maleic acid, lactic acid, salts with carboxylic acids such as malic acid, glutamic acid, aspartic acid; methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, etc.
- Salts with sulfonic acids salts with alkali metals such as sodium and potassium; salts with inorganic bases such as salts with alkaline earth metals such as calcium; and triethylamine, piperidine, morpholine, pyridine, lysine, etc. And salts with organic bases.
- the dosage of the phenoxyacetic acid derivative represented by the general formula (I) or a pharmacologically acceptable salt or hydrate or solvate thereof depends on the patient's body weight, age, sex, disease, etc. It may be determined as appropriate according to the degree and the ex 1-AR blocker to be combined. In general, for adults, 1 to 1000 mgZ days for oral administration and 0.01 mg to 100 mgZ days for parenteral administration.
- Examples of a 1-AR blockers include silodosin, tamsulosin, prazosin, terazosin, naphthovir, and the like, and they can also be used as pharmacologically acceptable salts thereof. Of these, tamsulosin and silodosin, which are highly selective for ⁇ 1-AR, are preferred.
- the dose of a 1-AR blocker is appropriately determined according to the patient's weight, age, sex, and degree of disease. Just decide.
- the oral dosage for adults is 1 to 16 mgZ days for silodosin, 0.1 to 0.8 mgZ days for tamsulosin hydrochloride, 1 to 12 mgZ days for prazosin hydrochloride, and 25 to 150 mg / day for naphthopidyl.
- a medicament comprising a combination of a phenoxyacetic acid derivative represented by the general formula (I) and the ex 1-AR blocker is a single preparation comprising the phenoxyacetic acid derivative and an a1-AR blocker.
- it may be a combination preparation in which the preparation containing the phenoxyacetic acid derivative and the preparation containing the oc 1-AR blocker are administered separately at the same time or at intervals.
- the administration route of each preparation may be the same or different.
- a medicament comprising the phenoxyacetic acid derivative and a 1-AR blocker comprises the phenoxyacetic acid derivative and the 1-AR blocker, and an appropriate excipient, disintegrant, binder, lubricant, dilution Agents, buffers, isotonic agents, preservatives, wetting agents, emulsifiers, dispersants, stabilizers, solubilizers, etc. be able to.
- an appropriate excipient disintegrant, binder, lubricant, dilution Agents, buffers, isotonic agents, preservatives, wetting agents, emulsifiers, dispersants, stabilizers, solubilizers, etc. be able to.
- available single preparations can be used for the combined preparations such as the phenoxyacetic acid derivative and the ex 1-AR blocker.
- the combination pharmaceutical composition of the present invention may be combined with other drugs effective for frequent urination and urinary incontinence, if necessary.
- Other effective drugs for frequent urination and urinary incontinence include, for example, anticholinergic drugs, 2-adrenergic receptor agonists, estrogen preparations, central nervous system drugs (selective serotonin reuptake inhibitors, serotonin'norphepinephrine reuptakes) Inhibitors, neurocun receptor antagonist, potassium channel opener, vanilloid receptor antagonist, vasopressin 2 receptor antagonist, GABA receptor antagonist, serotonin receptor antagonist, Examples include donomin receptor agonists, antiallergic drugs, non-sterolide anti-inflammatory drugs, and NO synthesis inhibitors.
- a combination of a phenoxyacetic acid derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof or a hydrate or solvate thereof, and an a 1-AR blocking agent of the present invention exhibits an excellent effect of reducing intravesical pressure or extending the interval of urination. Therefore, according to the present invention, a prophylactic or therapeutic drug that is extremely useful for frequent urination or urinary incontinence can be provided.
- FIG. 1 shows the intravesical pressure lowering action of each drug in anesthetized rats.
- the bar graph shows data for tamsulosin hydrochloride alone, compound 1 alone, and the combination of tamsulosin hydrochloride and compound 1 from the left.
- the vertical axis shows the bladder pressure lowering effect as a percentage of the maximum lowering effect by isoproterenol.
- FIG. 2 shows the urination interval extending action of each drug in acetic acid-stimulated rats.
- the bar graph shows data of solvent, silodosin alone, compound 2 alone, and combination of silodosin and compound 2 from the left.
- the vertical axis shows the effect of extending the micturition interval as a percentage of the pre-dose value.
- isoproterenol was intravenously administered at 10 mg / kg, and the maximum reduction effect was 100%.
- rat urinary bladder pressure-lowering effects were 26%, 37%, and 74% for tamsulosin hydrochloride alone, compound 1 alone, and tamsulosin hydrochloride and compound 1 respectively.
- the female rat was anesthetized with urethane, the midline incision was made in the abdomen, the bilateral ureters were ligated and cut, and the renal stump was opened.
- a force-yure was inserted from the top of the bladder, and an intravesical pressure measurement channel and an intravesical injection channel were secured via a three-way stopcock.
- a pressure transducer was connected to the other end of the bladder force nucleus, and the intravesical pressure was measured.
- Saline was continuously infused into the bladder (3.6 mL / hr).
- Acetic acid solution (0.25%) was continuously infused into the bladder (3.6 mL / hr) to induce shortening of the urination interval.
- silodosin (0.03 mg / kg), (1) 2— [4— [2— [[(IS, 2R) 2-hydroxy-2— (4-hydroxyphenyl) -1-methylethyl] ] Amino] ethyl] 2,5-dimethyldimethyl] acetic acid (hereinafter referred to as “compound 2”) (1 mg / kg), or silodosin (0.03 mg / kg) and compound 2 (1 mg / kg) Both of these drugs were administered from the femoral vein force ure, and the time until urination occurred and the next urination was induced (urination interval) was measured.
- the phenoxyacetic acid derivative represented by the general formula (I) and the ex 1-AR blocker are used in combination, the phenoxyacetic acid derivative represented by the general formula (I) is ex 1- It can be seen that the action of the AR blocker is enhanced, or that the a 1-AR blocker enhances the action of the phenoxyacetic acid derivative to have a synergistic urination interval extending action.
- a combination of a phenoxyacetic acid derivative represented by the general formula (I) or a pharmacologically acceptable salt or hydrate or solvate thereof and an a 1-AR blocker exhibits an excellent effect of reducing intravesical pressure or extending the interval of urination. Therefore, the present invention can provide a prophylactic or therapeutic agent extremely useful for frequent urination or urinary incontinence.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK05721012.2T DK1728508T3 (da) | 2004-03-24 | 2005-03-17 | Farmaceutisk produkt til forebyggelse eller behandling af hyppig vandladning eller inkontinens |
US10/599,203 US20080242674A1 (en) | 2004-03-24 | 2005-03-17 | Medicine For Prevention or Treatment of Frequent Urination or Urinary Incontinence |
JP2006511224A JP4808613B2 (ja) | 2004-03-24 | 2005-03-17 | 頻尿または尿失禁の予防または治療用医薬 |
AT05721012T ATE442137T1 (de) | 2004-03-24 | 2005-03-17 | Medikament zur prävention oder behandlung von häufigem harndrang oder harninkontinenz |
CA002559646A CA2559646A1 (en) | 2004-03-24 | 2005-03-17 | Medicine for prevention or treatment of frequent urination or urinary incontinence |
PL05721012T PL1728508T3 (pl) | 2004-03-24 | 2005-03-17 | Lek użyteczny do zapobiegania lub leczenia częstomoczu lub nietrzymania moczu |
SI200530851T SI1728508T1 (sl) | 2004-03-24 | 2005-03-17 | Zdravilo za preprečevanje ali zdravljenje pogostega uriniranja ali urinske inkontinence |
DE602005016534T DE602005016534D1 (de) | 2004-03-24 | 2005-03-17 | Medikament zur prävention oder behandlung von häufigem harndrang oder harninkontinenz |
EP05721012A EP1728508B1 (en) | 2004-03-24 | 2005-03-17 | Medicine for prevention or treatment of frequent urination or urinary incontinence |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JPPCT/JP2004/004000 | 2004-03-24 | ||
PCT/JP2004/004000 WO2005092321A1 (ja) | 2004-03-24 | 2004-03-24 | 頻尿または尿失禁の予防または治療用医薬組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005089742A1 true WO2005089742A1 (ja) | 2005-09-29 |
WO2005089742A8 WO2005089742A8 (ja) | 2005-11-03 |
Family
ID=34993428
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/004000 WO2005092321A1 (ja) | 2004-03-24 | 2004-03-24 | 頻尿または尿失禁の予防または治療用医薬組成物 |
PCT/JP2005/004825 WO2005089742A1 (ja) | 2004-03-24 | 2005-03-17 | 頻尿または尿失禁の予防または治療用医薬 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/004000 WO2005092321A1 (ja) | 2004-03-24 | 2004-03-24 | 頻尿または尿失禁の予防または治療用医薬組成物 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20080242674A1 (ja) |
EP (1) | EP1728508B1 (ja) |
AT (1) | ATE442137T1 (ja) |
CA (1) | CA2559646A1 (ja) |
CY (1) | CY1109546T1 (ja) |
DE (1) | DE602005016534D1 (ja) |
DK (1) | DK1728508T3 (ja) |
ES (1) | ES2331369T3 (ja) |
PL (1) | PL1728508T3 (ja) |
PT (1) | PT1728508E (ja) |
SI (1) | SI1728508T1 (ja) |
WO (2) | WO2005092321A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1769792A1 (de) * | 2005-09-30 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co.KG | Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden |
JP2009520776A (ja) * | 2005-12-22 | 2009-05-28 | ユロスフェール・エスアエス | 失禁治療方法 |
WO2010053068A1 (ja) * | 2008-11-07 | 2010-05-14 | 大日本住友製薬株式会社 | 新規で有用な下部尿路症状治療剤 |
JP2010540621A (ja) * | 2007-10-02 | 2010-12-24 | ドン ア ファーマシューティカル カンパニー リミテッド | 良性前立腺肥大症および下部尿路症状の治療または予防用組成物、およびその治療または予防方法 |
US8013007B2 (en) | 2007-02-26 | 2011-09-06 | Concert Pharmaceuticals, Inc. | Alpha 1A-adrenoceptor antagonists |
WO2013027806A1 (ja) * | 2011-08-25 | 2013-02-28 | キッセイ薬品工業株式会社 | 低活動膀胱の予防または治療用医薬組成物 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6426517A (en) * | 1987-07-21 | 1989-01-27 | Sankyo Co | Remedy for dysuria |
WO2000002846A1 (en) * | 1998-07-08 | 2000-01-20 | Kissei Pharmaceutical Co., Ltd. | Phenoxyacetic acid derivatives and medicinal compositions containing the same |
JP2001114679A (ja) * | 1999-08-09 | 2001-04-24 | Yamanouchi Pharmaceut Co Ltd | 下部尿路症治療剤 |
JP2001288115A (ja) | 2001-02-07 | 2001-10-16 | Yamanouchi Pharmaceut Co Ltd | 下部尿路症治療剤 |
WO2002069906A2 (en) | 2001-03-06 | 2002-09-12 | Cellegy Pharmaceuticals, Inc. | Compounds and methods for the treatment of urogenital disorders |
JP2003055261A (ja) * | 2001-08-08 | 2003-02-26 | Pfizer Prod Inc | 製剤組合せ |
WO2003024916A1 (fr) * | 2001-09-13 | 2003-03-27 | Kissei Pharmaceutical Co., Ltd. | Cristaux d'un derive d'hydroxynorephedrine |
WO2005042021A2 (de) | 2003-11-03 | 2005-05-12 | Boehringer Ingelheim International Gmbh | Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einen alpha antagonisten und/oder einen 5-alpha reduktase-hemmer |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE504276C2 (sv) * | 1993-12-30 | 1996-12-23 | Siko Medical Ab | Ventil avsedd att placeras i urinröret |
US6262115B1 (en) * | 1995-05-22 | 2001-07-17 | Alza Coporation | Method for the management of incontinence |
US20020143007A1 (en) * | 1996-02-02 | 2002-10-03 | Garvey David S. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use |
US6410554B1 (en) * | 1998-03-23 | 2002-06-25 | Merck & Co., Inc. | Combination therapy for the treatment of benign prostatic hyperplasia |
IL141235A (en) * | 2000-02-09 | 2012-04-30 | Novartis Int Pharm Ltd | Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia |
JP4132020B2 (ja) * | 2001-03-12 | 2008-08-13 | キッセイ薬品工業株式会社 | フェノキシ酢酸誘導体の製造中間体およびその使用方法 |
JP5004215B2 (ja) * | 2004-03-05 | 2012-08-22 | キッセイ薬品工業株式会社 | 神経障害に伴う過活動膀胱の予防または治療用医薬組成物 |
-
2004
- 2004-03-24 WO PCT/JP2004/004000 patent/WO2005092321A1/ja active Application Filing
-
2005
- 2005-03-17 ES ES05721012T patent/ES2331369T3/es active Active
- 2005-03-17 DE DE602005016534T patent/DE602005016534D1/de active Active
- 2005-03-17 AT AT05721012T patent/ATE442137T1/de active
- 2005-03-17 PT PT05721012T patent/PT1728508E/pt unknown
- 2005-03-17 WO PCT/JP2005/004825 patent/WO2005089742A1/ja not_active Application Discontinuation
- 2005-03-17 PL PL05721012T patent/PL1728508T3/pl unknown
- 2005-03-17 EP EP05721012A patent/EP1728508B1/en not_active Not-in-force
- 2005-03-17 DK DK05721012.2T patent/DK1728508T3/da active
- 2005-03-17 US US10/599,203 patent/US20080242674A1/en not_active Abandoned
- 2005-03-17 SI SI200530851T patent/SI1728508T1/sl unknown
- 2005-03-17 CA CA002559646A patent/CA2559646A1/en not_active Abandoned
-
2009
- 2009-12-04 CY CY20091101275T patent/CY1109546T1/el unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6426517A (en) * | 1987-07-21 | 1989-01-27 | Sankyo Co | Remedy for dysuria |
WO2000002846A1 (en) * | 1998-07-08 | 2000-01-20 | Kissei Pharmaceutical Co., Ltd. | Phenoxyacetic acid derivatives and medicinal compositions containing the same |
JP2001114679A (ja) * | 1999-08-09 | 2001-04-24 | Yamanouchi Pharmaceut Co Ltd | 下部尿路症治療剤 |
JP2001288115A (ja) | 2001-02-07 | 2001-10-16 | Yamanouchi Pharmaceut Co Ltd | 下部尿路症治療剤 |
WO2002069906A2 (en) | 2001-03-06 | 2002-09-12 | Cellegy Pharmaceuticals, Inc. | Compounds and methods for the treatment of urogenital disorders |
JP2003055261A (ja) * | 2001-08-08 | 2003-02-26 | Pfizer Prod Inc | 製剤組合せ |
WO2003024916A1 (fr) * | 2001-09-13 | 2003-03-27 | Kissei Pharmaceutical Co., Ltd. | Cristaux d'un derive d'hydroxynorephedrine |
WO2005042021A2 (de) | 2003-11-03 | 2005-05-12 | Boehringer Ingelheim International Gmbh | Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einen alpha antagonisten und/oder einen 5-alpha reduktase-hemmer |
Non-Patent Citations (2)
Title |
---|
"Iyaku Journal", vol. 33, 1997, IYAKU-JOURNAL COMPANY, pages: 193 - 197 |
"Scope", vol. 42, 2003, PHARMACIA COMPANY, pages: 14 - 15 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1769792A1 (de) * | 2005-09-30 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co.KG | Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden |
WO2007036543A1 (de) * | 2005-09-30 | 2007-04-05 | Boehringer Ingelheim International Gmbh | Verwendung eines beta-3-adrenozeptor-agonisten zur behandlung von nieren- und blasenbeschwerden |
JP2009520776A (ja) * | 2005-12-22 | 2009-05-28 | ユロスフェール・エスアエス | 失禁治療方法 |
US8013007B2 (en) | 2007-02-26 | 2011-09-06 | Concert Pharmaceuticals, Inc. | Alpha 1A-adrenoceptor antagonists |
JP2010540621A (ja) * | 2007-10-02 | 2010-12-24 | ドン ア ファーマシューティカル カンパニー リミテッド | 良性前立腺肥大症および下部尿路症状の治療または予防用組成物、およびその治療または予防方法 |
WO2010053068A1 (ja) * | 2008-11-07 | 2010-05-14 | 大日本住友製薬株式会社 | 新規で有用な下部尿路症状治療剤 |
WO2013027806A1 (ja) * | 2011-08-25 | 2013-02-28 | キッセイ薬品工業株式会社 | 低活動膀胱の予防または治療用医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
SI1728508T1 (sl) | 2010-01-29 |
US20080242674A1 (en) | 2008-10-02 |
DK1728508T3 (da) | 2010-01-25 |
WO2005092321A1 (ja) | 2005-10-06 |
PT1728508E (pt) | 2009-10-20 |
EP1728508A4 (en) | 2008-02-13 |
DE602005016534D1 (de) | 2009-10-22 |
CY1109546T1 (el) | 2014-08-13 |
CA2559646A1 (en) | 2005-09-29 |
ATE442137T1 (de) | 2009-09-15 |
PL1728508T3 (pl) | 2010-02-26 |
EP1728508B1 (en) | 2009-09-09 |
WO2005089742A8 (ja) | 2005-11-03 |
ES2331369T3 (es) | 2009-12-30 |
EP1728508A1 (en) | 2006-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050131049A1 (en) | Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence | |
WO2005089742A1 (ja) | 頻尿または尿失禁の予防または治療用医薬 | |
WO2003006019A1 (fr) | Composition medicinale destinee au traitement de la cystite interstitielle | |
JP2012507484A (ja) | αアドレナリン受容体拮抗薬と抗ムスカリン薬の併用 | |
WO2006090759A1 (ja) | ソリフェナシン含有医薬 | |
EP1724257B1 (en) | Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder | |
US20030225118A1 (en) | Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention | |
US20100137399A1 (en) | Preventive and/or therapeutic agent for urine collection disorder accompanying lower urinary tract obstruction | |
JP4808613B2 (ja) | 頻尿または尿失禁の予防または治療用医薬 | |
US20100331361A1 (en) | Pharmaceutical composition containing alpha-adrenergic receptor antagonist and an anti-muscarinic agent and method of improving lower urinary tract symptoms associated with prostatic hypertrophy | |
US9603845B2 (en) | Prophylactic agent and/or therapeutic agent for stress urinary incontinence | |
AU2016301689B2 (en) | Ameliorating agent for detrusor hyperactivity with impaired contractility | |
US20040142929A1 (en) | Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence | |
Fridrich et al. | Phase 1A safety assessment of intravenous amitriptyline | |
TWI356699B (en) | Agent for treating interstitial cystitis and agent | |
JPH08259440A (ja) | 急性尿閉治療用脱アセチル化モキシシライト | |
JP4602969B2 (ja) | 過活動膀胱を治療するためのフェノキシ酢酸誘導体の使用 | |
TWI836234B (zh) | 排尿症狀治療劑 | |
JP6894555B1 (ja) | 排尿症状治療剤 | |
JPWO2007083640A1 (ja) | 頻尿及び尿失禁の予防又は治療剤 | |
EP4176873A1 (en) | Urinary symptom therapeutic agent | |
TW201043610A (en) | Methods of treating bladder dysfunction using netupitant | |
JP2010013441A (ja) | 過活動膀胱治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
CFP | Corrected version of a pamphlet front page |
Free format text: UNDER (57) PUBLISHED ABSTRACT IN JAPANESE REPLACED BY CORRECT ABSTRACT |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006511224 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2559646 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005721012 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10599203 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005721012 Country of ref document: EP |